Wesbanco Bank Inc. Sells 4,762 Shares of Johnson & Johnson (NYSE:JNJ)

Wesbanco Bank Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,304 shares of the company’s stock after selling 4,762 shares during the period. Johnson & Johnson accounts for about 0.8% of Wesbanco Bank Inc.’s holdings, making the stock its 24th largest holding. Wesbanco Bank Inc.’s holdings in Johnson & Johnson were worth $24,844,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. CX Institutional raised its position in Johnson & Johnson by 35.4% during the 3rd quarter. CX Institutional now owns 49,167 shares of the company’s stock valued at $7,968,000 after purchasing an additional 12,856 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Johnson & Johnson by 25.6% in the 3rd quarter. Sivia Capital Partners LLC now owns 4,592 shares of the company’s stock worth $744,000 after buying an additional 935 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Johnson & Johnson by 2.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after buying an additional 86 shares during the last quarter. Fiduciary Alliance LLC grew its stake in shares of Johnson & Johnson by 13.9% in the 3rd quarter. Fiduciary Alliance LLC now owns 73,493 shares of the company’s stock worth $11,910,000 after buying an additional 8,978 shares during the last quarter. Finally, Granite Harbor Advisors Inc. grew its stake in shares of Johnson & Johnson by 10.7% in the 3rd quarter. Granite Harbor Advisors Inc. now owns 8,654 shares of the company’s stock worth $1,402,000 after buying an additional 839 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $161.60 on Tuesday. The business’s fifty day moving average is $162.60 and its 200 day moving average is $154.48. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a market capitalization of $388.92 billion, a PE ratio of 10.07, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the previous year, the business earned $2.80 earnings per share. The business’s revenue was up 4.3% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. Johnson & Johnson’s payout ratio is 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada raised their price target on Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.